ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.086,24
0,22%
Brent Oil
83,76
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Novavax Inc (NVAX)

  7. Novavax Inc (NVAX) Notícias

NVAX

Novavax (NVAX)

Novavax Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NVAX
DataHoraFonteTítuloCódigoCompanhia
15/05/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVAXNovavax Inc
14/05/202418:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVAXNovavax Inc
13/05/202417:10Edgar (US Regulatory)Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialNASDAQ:NVAXNovavax Inc
13/05/202417:02PR Newswire (US)Novavax to Participate in BofA Securities 2024 Health Care ConferenceNASDAQ:NVAXNovavax Inc
13/05/202415:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVAXNovavax Inc
10/05/202409:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NVAXNovavax Inc
10/05/202409:02IH Market NewsNovavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More NewsNASDAQ:NVAXNovavax Inc
10/05/202403:15PR Newswire (US)Novavax Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:NVAXNovavax Inc
10/05/202403:00PR Newswire (US)Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination VaccinesNASDAQ:NVAXNovavax Inc
07/05/202415:43Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NVAXNovavax Inc
07/05/202410:25PR Newswire (US)Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024NASDAQ:NVAXNovavax Inc
07/05/202408:44IH Market NewsTesla’s April Sales Down 18% in China, Amazon’s Multi-Billion Dollar Cloud Expansion in Singapore, and More NewsNASDAQ:NVAXNovavax Inc
06/05/202407:22GlobeNewswire Inc.Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual MeetingNASDAQ:NVAXNovavax Inc
15/04/202407:00GlobeNewswire Inc.Shah Capital nominates two highly qualified independent director candidates for NovavaxNASDAQ:NVAXNovavax Inc
01/04/202409:00PR Newswire (US)Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024NASDAQ:NVAXNovavax Inc
29/02/202418:02PR Newswire (US)Novavax to Participate in TD Cowen's 44th Annual Health Care ConferenceNASDAQ:NVAXNovavax Inc
28/02/202410:00PR Newswire (US)Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:NVAXNovavax Inc
28/02/202409:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NVAXNovavax Inc
23/02/202410:03IH Market NewsGoldman Sachs Reconsiders Fed Cuts, LUNR Surges Over 40% in Pre-Market, and MoreNASDAQ:NVAXNovavax Inc
22/02/202408:00PR Newswire (US)Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase AgreementNASDAQ:NVAXNovavax Inc
20/02/202411:25PR Newswire (US)Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024NASDAQ:NVAXNovavax Inc
03/01/202411:25PR Newswire (US)Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NVAXNovavax Inc
18/12/202310:00PR Newswire (US)Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in TaiwanNASDAQ:NVAXNovavax Inc
13/12/202319:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NVAXNovavax Inc
13/12/202310:31Dow Jones NewsModerna Shares, Other Covid Vaccine Makers Hit by Warning From PfizerNASDAQ:NVAXNovavax Inc
13/12/202310:00PR Newswire (Canada)Canadians Can Help Protect Loved Ones as We Head into the Holiday SeasonNASDAQ:NVAXNovavax Inc
05/12/202318:01PR Newswire (Canada)Novavax's Updated COVID-19 Vaccine Now Authorized in CanadaNASDAQ:NVAXNovavax Inc
28/11/202315:13IH Market NewsWall Street Radar: Amazon, Blackrock, General Motors, Eli Lilly, Novavax..NASDAQ:NVAXNovavax Inc
28/11/202308:00PR Newswire (US)Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health OrganizationNASDAQ:NVAXNovavax Inc
17/11/202309:15PR Newswire (US)Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic PrioritiesNASDAQ:NVAXNovavax Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NVAX

Seu Histórico Recente

NYSE
DVA
DaVita
OKEX
ELONUSDT
Dogelon
NYSE
PTJ
BOV
BBAS3Q
BANCO DO BRASIL ON
LSE
0QP6
Leclanche
NYSE
PEF
TSX
XSU
iShares US Small Cap Ind...
LSE
0RP8
Liechtensteinische Lande...
LSE
AMER
Amerisur Resources
LSE
0IFM
Egain
BOV
N1DA34
NASDAQ
BOV
PINE4R
PINE PN
AMEX
UTG
Reaves Utility Income
XE
CEC
Ceconomy
BOV
MRVEE670
MRVEE670 Ex:6,7
NYSE
FEI
First Trust MLP and Ener...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados